AVIR stock Statistics — Atea Pharmaceuticals, Inc. filings, insiders & smart money

Price and daily changeSign in

Earnings11 Nov 2026

52-week rangeSign inDay rangeSign in

Price chart (1D to 10Y)

Licensed market data — shown to members, not published to the open web.

Beta: Sign in
Shares outstandingAs of 2026-08-10 · filed common shares: 80.20M
Shares float: Sign in
Float %: Sign in
Insider ownershipDirectors and officers, from their latest Form 3/4/5 holding: 3.51%
Institutional ownership: Sign in
Short interestShare of shares outstanding, at settlement: 9.56%
Short ratioDays to cover, as published by FINRA: 41.16
Short volume (5D)Share of FINRA reporting-facility volume sold short, daily flow: 63.20%
Short volume (20D)Share of FINRA reporting-facility volume sold short, daily flow: 66.90%
Avg volume (10D)

Source: SEC filings. Information and analytics, not investment advice.

Rev growth (fwd)

Avg volume (3 months)

Gross margin: —
Operating margin: —
Net margin: —
EBITDA margin: —
Return on equityNet income (TTM to Jun 26) ÷ average shareholders equity: -58.14%
Return on assetsNet income (TTM to Jun 26) ÷ average total assets: -52.99%

Sign in

Price / operating cash flow

P/FCF

EV / revenue

EV / EBITDA

EPSDiluted, TTM to Jun 26

-2.08

EPS (fwd)

Cash & equivalentsas of Jun 26: $76.54M
Total cash: Sign in
Total debtBorrowings + finance and operating lease liabilities, as of Jun 26: $424.00K
Debt / equityas of Jun 26: 0.21%
Current ratioas of Jun 26: 8.13
Quick ratio: —
Operating cash flowTTM to Jun 26: -$152.07M
Free cash flowUnadjusted FCF = CFO − capex · TTM to Jun 26: -$152.07M
TTM revenue / diluted share: —